3 results about "INTESTINAL CARCINOMA" patented technology

The present application relates to the application of ocanin in the preparation of anti-tumor drugs, and the ocanin is used in the anti-tumor drugs alone or in combination with 5-fluorouracil, and the concentration of the ocanin used in the preparation of anti-intestinal cancer drugs is 20-500 uMol. It is found that the ocanin can inhibit the growth of intestinal cancer cells in vivo and in vitro, and the naked mice have good tolerance to the natural compound. The ocanin has better anti-intestinal cancer effect than other extracts of goldeneye and devil's needle, and has better anti-cancer effect and smaller toxicity than the current conventional intestinal cancer drug 5-fluorouracil. Therefore, the ocanin can be developed into a new anti-cancer drug.

The application belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound in preparation of a cancer treatment drug, wherein the benzothiazepine compound has a structural formula as shown in formula I, and the cancer is at least one selected from liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment of the application, it is found that the compound shown in formula I shows clear and different activities on human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventors of the application find, for the first time, through activity screening on a small molecule skeleton, that the benzothiazepine compound shown in formula I has excellent activity on various different types of human tumors, and the benzothiazepine compound provides an optional scheme for a broad-spectrum anticancer drug.

A method for treating a microsatellite-stable (MSS) solid tumor is provided. The method includes administering a therapeutically effective amount of icariside I to a subject suffering from the MSS solid tumor. The method further includes administering a combination anti-cancer active agent to the subject, the combination anti-cancer active agent includes an immunotherapeutic agent (for example, a PD-1 / PD-L1 inhibitor and / or a CAR-T therapy product). A use of the icariside I in the preparation of a drug for treating or preventing the MSS solid tumor, particularly a MSS gastric cancer, a MSS intestinal cancer, a MSS lung cancer, a MSS pancreatic cancer, and a MSS hepatocellular carcinoma, and a kit including the same are further provided. A use of a combination of the icariside I and the immunotherapeutic agent in the preparation of a drug for treating or preventing the MSS solid tumor.